M A Karsdal1, K M Verburg2, C R West3, A C Bay-Jensen4, D S Keller5, R H G P Arends6. 1. Nordic Bioscience, Herlev Hovedgade, DK-2730 Herlev, Denmark. Electronic address: mk@nordicbio.com. 2. Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA. Electronic address: Kenneth.M.Verburg@pfizer.com. 3. Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA. Electronic address: Christine.West@pfizer.com. 4. Nordic Bioscience, Herlev Hovedgade, DK-2730 Herlev, Denmark. Electronic address: acbj@nordicbio.com. 5. Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA. Electronic address: David.S.Keller@pfizer.com. 6. Pfizer Inc., 445 Eastern Point Road, Groton, CT 06340, USA. Electronic address: Rosalin.Arends@pfizer.com.
Abstract
There is a need for efficacious and safe pain treatments for OA (osteoarthritis). The nerve growth factor (NGF) antibody tanezumab is associated with high efficacy, but when combined with chronic NSAID treatment shows an increased risk of rapidly progressive osteoarthritis (RPOA) in a small group of patients. AIM: The aim of this study was to phenotype with biochemical biomarkers of bone, cartilage, soft tissue, synovial metabolism OA patients who are at risk of developing RPOA type-2, for both limited and chronic NSAIDs users. MATERIAL AND METHODS: The dataset consisted of OA patients participating in tanezumab trials who used NSAIDs <90 days (limited NSAID users) or chronic users (NSAIDs ≥90 days) over an average 10 month period. Biomarker data were available for 47 cases (RPOA type-2) and 92 controls. Non-linear and linear multivariable predictive models were developed. RESULTS: By use of two biomarkers at baseline the receiver operating characteristic (ROC) curve area for RPOA type-2 in limited NSAID users was 71%, [CI] (60-83%). OA subjects with this biomarker phenotype had 8-fold higher confidence interval [CI][(2-33)] relative risk of developing RPOA type-2 as compared to OA patients without this phenotype. The AUC of the model in chronic NSAIDs users based on 5 biomarkers was 78%, [CI](69-88%), with 4-fold [CI (2-6)] relative risk of developing RPOA type-2. CONCLUSION: In this hypothesis generating and exploratory study, we identified combinations of biomarkers associated with OA patients who develop RPOA type-2, which may be related to the pathology of the RPOA type-2 joint.
RCT Entities:
There is a need for efficacious and safe pain treatments for OA (osteoarthritis). The nerve growth factor (NGF) antibody tanezumab is associated with high efficacy, but when combined with chronic NSAID treatment shows an increased risk of rapidly progressive osteoarthritis (RPOA) in a small group of patients. AIM: The aim of this study was to phenotype with biochemical biomarkers of bone, cartilage, soft tissue, synovial metabolism OApatients who are at risk of developing RPOA type-2, for both limited and chronic NSAIDs users. MATERIAL AND METHODS: The dataset consisted of OA patients participating in tanezumab trials who used NSAIDs <90 days (limited NSAID users) or chronic users (NSAIDs ≥90 days) over an average 10 month period. Biomarker data were available for 47 cases (RPOA type-2) and 92 controls. Non-linear and linear multivariable predictive models were developed. RESULTS: By use of two biomarkers at baseline the receiver operating characteristic (ROC) curve area for RPOA type-2 in limited NSAID users was 71%, [CI] (60-83%). OA subjects with this biomarker phenotype had 8-fold higher confidence interval [CI][(2-33)] relative risk of developing RPOA type-2 as compared to OA patients without this phenotype. The AUC of the model in chronic NSAIDs users based on 5 biomarkers was 78%, [CI](69-88%), with 4-fold [CI (2-6)] relative risk of developing RPOA type-2. CONCLUSION: In this hypothesis generating and exploratory study, we identified combinations of biomarkers associated with OA patients who develop RPOA type-2, which may be related to the pathology of the RPOA type-2 joint.
Authors: Jeffrey B Driban; Matthew S Harkey; Mary F Barbe; Robert J Ward; James W MacKay; Julie E Davis; Bing Lu; Lori Lyn Price; Charles B Eaton; Grace H Lo; Timothy E McAlindon Journal: BMC Musculoskelet Disord Date: 2020-05-29 Impact factor: 2.362